Clinical trial
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB…
NCT00016367 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00016367 |
|---|---|
| Title | Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | Phase II Multidose, Single Arm, Multicenter Clinical Trial of Cisplatin and Gemcitabine in Combination With Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local Stage (Stage IIIb Pleural Effusion Only) and… |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | Trastuzumab, Cisplatin, Gemcitabine Hydrochloride |
| Enrollment | 22 |
| Start date | May 13, 1999 |
| Primary completion | Dec 14, 2004 |
| Completion | Dec 14, 2004 |
| First posted | Feb 27, 2004 |
| Last update posted | Oct 26, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: